INTRODUCTION
The tumor status of the regional lymph nodes is the most important prognostic indicator for patients with breast cancer. However, 20% to 30% of nodenegative patients will develop a recurrence and die of their disease. [1] [2] [3] It has been postulated that this phenomenon may be, in part, a result of undetected lymph node metastases or metastatic deposits that are too small for detection by standard histopathologic evaluation and that, if not identified, may lead to undertreatment. Veronesi et al 2 reported a 20-year rate of death from breast cancer of 20.8% in node-negative patients who received no systemic therapy. They noted that the incidence of lymph node involvement in a recent study of clinical T1N0 patients was 36% compared with a 26% incidence in their earlier trials before the adoption of sentinel node biopsy (SNB), implying that prior trials underestimated the extent of disease and some patients felt to be node negative were actually node positive.
Cancer staging as defined by the American Joint Committee on Cancer (AJCC) guidelines relies heavily on the status of the lymph nodes. Lymph node metastases have been traditionally identified with routine hematoxylin and eosin (HE) staining. In recent years, however, more sophisticated histopathologic evaluation of sentinel node (SN) has increasingly identified a subgroup of patients with micrometastatic disease or small clusters of isolated tumor cells (ITCs) usually identified by immunohistochemical (IHC) stains. 4 It is possible that patients with IHC-positive lymph nodes account for a large portion of the node-negative women who develop recurrent or metastatic carcinoma. The sixth edition of the AJCC staging system incorporates the histopathologic work-up of the SN in its staging system. 5 A SN is defined as pN0 if there is no evidence of tumor on HE, pN0(iϩ) if there is a tumor deposit Յ 0.2 mm (ITC), pN1mi (micrometastases) if there is a tumor deposit greater than 0.2 mm and Յ 2 mm, and pN1 if the tumor deposit is more than 2 mm (macrometastases).
The impact of micrometastases or ITCs on local or distant recurrence as well as on overall survival (OS) has not been well defined and is a subject of great interest that may impact therapy. The emergence of SNB over the past decade has reduced the size of the staging nodal specimen, thereby allowing its evaluation with multiple sections and IHC in addition to standard HE. Although this focused examination can detect small clusters and even individual cells, the significance of these micrometastases and ITCs has not yet been determined. Therefore, we prospectively examined the clinical impact of ITCs and micrometastases in the SNs of patients with invasive breast cancer.
PATIENTS AND METHODS
Consecutive patients with clinical stage I, II, or III invasive breast cancer were enrolled from January 1, 1992, through April 1, 1999. Patients were excluded for the following reasons: ductal carcinoma in situ alone, bilateral breast cancer, neoadjuvant chemotherapy, clinically suspicious lymph nodes, or stage IV disease at presentation. All patients signed an informed consent form in accordance with the ethical standards of the John Wayne Cancer Institute's Institutional Review Board (Santa Monica, CA).
All patients underwent intraoperative lymphatic mapping of the SN as described previously. 6 Our technique for focused histologic examination of the SN has previously been described. 7, 8 In brief, each SN was bisected and blocked, prepared for permanent sectioning, and stained with standard HE techniques. If negative, six to eight sections of the SN were submitted for IHC analysis using monoclonal antibodies directed against low and intermediate molecular weight cytokeratins (MAK-6; Ciba-Corning, Alameda, CA).
The patients were stratified into four groups based on the size of the SN metastases according to the AJCC sixth edition staging system. Patients were observed at the John Wayne Cancer Institute Breast Center or their medical oncologist's office for signs of recurrence. A few patients in each group were contacted by phone. The US Social Security Death Index was reviewed to confirm deaths.
Statistical Analysis
Patients were stratified into the following four groups based on the size of the SN metastases: negative, pN0(i-): patients with no evidence of tumor with both HE and IHC stain; ITC, pN0(iϩ): patients with ITCs or deposits Յ 0.2 mm detected by IHC or HE; micrometastases, pN1mi: patients with a tumor deposit more than 0.2 mm and Յ 2 mm identified by HE; and macrometastases, pN1: patients with a tumor deposit more than 2 mm identified by HE.
Disease-free survival (DFS) and OS rates were calculated using the Kaplan-Meier method, and univariate and multivariate analyses were performed using the log-rank test and Cox regression analysis. Proportional hazard assumptions were checked by plotting log [-log (estimated survival distribution function)] versus log (survival time), and it was confirmed that they were not violated in the Cox proportional hazards regression analyses. Goodness of fit for the model was assessed by residual plots, and no unusual pattern or deviance was found.
RESULTS
The 790 patients in this study were divided into four groups based on the size of the SN metastases and clinical characteristics listed in Table 1 . Most patients presented with palpable masses, but nearly half of the node-negative group had cancers detected by screening mammogram.
The type of biopsy and surgical procedures are listed in Table 2 . Although the majority of patients in all four groups had an infiltrating ductal cancer, the prevalence of invasive lobular cancer was 25% in the ITC group and only 10% in the other groups (P ϭ .001, 2 test). The mean number of SNs was similar among the four groups and ranged from 1.89 to 1.98. Abbreviation: ITC, isolated tumor cell. Not surprisingly, there was a direct relationship between the size of the primary tumor and the presence of SN metastasis. The mean tumor size increased from 1.4 cm in the negative group to 2.2 cm in the ITC group, 2.1 cm in the micrometastases group, and 2.9 cm in the macrometastases group (Table 1) . As the size of the SN metastases increased, the detection of nonsentinel node (NSN) metastases also increased, from 4% in the ITC group to 19% in the micrometastases group and 59% in the macrometastases group. The SN was the only positive node in 96% of the ITC group, 81% of the micrometastatic group, and 41% of the macrometastases group (P ϭ .001, 2 test). In patients with NSN involvement, the number of tumor-positive NSNs ranged from one to three nodes in the ITC group, one to seven nodes in the micrometastases group, and one to 32 nodes in the macrometastases group.
The majority of patients in this study (76.5%) received some form of adjuvant systemic therapy. Of those treated with adjuvant therapy, 43.9% received tamoxifen alone, 21.2% received chemotherapy alone, and 34.9% of patients received a combination of chemotherapy and tamoxifen. The use of adjuvant systemic therapy significantly correlated with SN metastasis (P ϭ .001). As the size of SN metastases increased, the use of adjuvant systemic therapy increased from 66.1% in the negative group to 92.8% in the macrometastases group (Table 3) .
At a median follow-up of 72.5 months, the size of SN metastases was a significant predictor of 8-year DFS (P Ͻ .0001) and 8-year OS (P Ͻ .001). There was no difference in 8-year DFS and 8-year OS between the negative, ITC, or micrometastases groups. However, there was a significant difference in 8-year DFS and 8-year OS for the macrometastases group (Fig 1) . Seventy-two percent of patients have been observed for more than 5 years, and only two patients in the negative group were lost to follow-up.
Univariate analysis with the log-rank test was used to determine whether the size of the SN metastases affected 8-year DFS and 8-year OS (Table 4 ). There was a statistically significant difference in 8-year DFS and 8-year OS based on the size of the SN metastases.
Multivariable Cox regression models (Table 5) were used in identifying significant predictors for both 8-year DFS and 8-year OS. Major known prognostic factors for survival (SN metastases, number of positive nodes, estrogen receptor status, age, tumor size, HER2-NEU status, and histologic differentiation) were included in the model. A forced entry model was used for covariable selection. Only the size of SN metastases (macrometastasis v other), tumor size, and histologic differentiation were significant predictors of 8-year DFS. Size of SN metastases, age of the patient, and estrogen receptor status were significant predictors for 8-year OS. Not surprisingly, older age predicted a greater risk of death, but not from breast cancer. Using a likelihood ratio test, it was confirmed that the size of SN metastasis had a greater effect than other significant factors (P Ͻ .0001; Table 5 ).
DISCUSSION
The prognostic significance of micrometastasis continues to be an area of great debate. Adjuvant therapy treatment decisions are commonly based on the primary tumor characteristics alone, making the detection of lymph node or bone marrow metastasis less likely to affect treatment. Are these small tumor deposits defined as pN0(iϩ) or pN1mi significant? Do they impart the same prognostic implications as N1 or N0(i-) disease? Our findings suggest that tumor deposits defined as pN0(iϩ) or pN1mi do not have the same significance as macrometastasis and do not adversely affect DFS or OS by 8 years. Many studies have evaluated the significance of micrometastasis, and these have resulted in conflicting conclusions. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Most of these studies are retrospective.
The identification of micrometastasis has been underestimated with the traditional evaluation of multiple axillary lymph nodes by HE examination of one or two central cross sections of the lymph nodes. This leaves a large part of the lymph node unevaluated. The time and expense of sectioning the large number of nodes removed with a classic level I or II axillary lymph node dissection (ALND) have limited the study of micrometastasis in the past.
SNB has allowed for a more focused histopathologic evaluation of only one or two SNs. In 1995, our group 4 demonstrated that IHC evaluation of SNs in breast cancer patients increased the detection of micrometastasis when compared with routine ALND. Other groups have consistently demonstrated an increased detection rate of metastatic tumor by additional sectioning and IHC stains of the SN. [20] [21] [22] [23] Because IHC stains can easily identify single cells or clusters of cells that are otherwise not easily identified, the use of IHC has become widespread. Unfortunately, this may lead to overtreatment. In our study, 92% of patients in the ITC group received some form of adjuvant systemic therapy compared with 66% of the node-negative group. SN results were not blinded and seem to have influenced the recommendation for adjuvant systemic therapy, suggesting, if not a stage shift, a shift in the mind of the treating physician regarding prognosis.
Colleoni et al 24 retrospectively evaluated the biologic features, adjuvant treatment recommendations, and prognosis of 1,959 patients with pT1-3, pN0, pN1mi, pN0iϩ, or pN1a disease. Patients with any evidence of nodal disease were more likely to be prescribed anthracycline-containing chemotherapy compared with node-negative patients. Statistically significant differences in DFS and the risk of distant metastases were observed for patients with minimal lymph node involvement versus patients with node-negative disease. Chagpar et al 25 reported the clinical outcome of patients with SN micrometastases detected by IHC. Fifteen (18%) of 84 patients had micrometastases identified on IHC. Of the 15 patients with micrometastases, five received adjuvant chemotherapy based on primary tumor features, and 10 patients did not. At a median follow-up time of 40.2 months, there was no significant difference in survival or development of metastatic disease between patients with and without IHCdetected micrometastases. Abbreviations: OS, overall survival; DFS, disease-free survival; HR, hazard ratio; SN, sentinel node; ITC, isolated tumor cell; ER, estrogen receptor.
‫ء‬
Sixteen patients had no positive nodes; 47 patients had one to three positive nodes; 241 patients had four to 10 positive nodes; and 486 patients had more than 10 positive nodes. Cox et al 26 retrospectively studied the impact of SN micrometastases on survival. N0(iϩ) disease in the SN had no significant effect on survival but was treated with ALND. If there was no residual disease identified in the ALND specimens of patients who had either N0(iϩ) or N1mi in the SN, there was no difference in survival compared with N0 patients.
Our group examined the Surveillance, Epidemiology, and End Results database to evaluate the impact of N1mi disease in patients diagnosed with invasive breast cancer between 1992 and 2003. 27 As the use of SNB increased, the incidence of N1mi disease increased from 2.3% to 7% among 209,720 patients. On multivariate analysis, micrometastases in lymph nodes were a significant prognostic indicator, displaying a survival difference between N0(i-) and N1 disease even after adjusting for tumor-and patient-related factors. However, this study was limited by the use of a large retrospective database with no information as to how lymph nodes were evaluated. The inability to determine which patients received adjuvant systemic therapy in this Surveillance, Epidemiology, and End Results study may mask the true impact of micrometastases.
In our prospective study, the size of metastases in the SN was a significant predictor of both DFS and OS. Most of this difference can be attributed to the differences between the negative/ITC and micrometastases groups versus the macrometastases group. In the macrometastases group, there was a significant difference in both DFS and OS at 8 years compared with the other groups. Comparing the negative, ITC, and micrometastases groups, there was no statistically significant difference in OS between the negative and micrometastases groups, but there was a difference between the ITC and negative groups, with a survival advantage for the ITC group. This survival advantage was also seen when the ITC group was compared with the micrometastases group. This difference can be explained by the fact that there have been no deaths in the ITC group to date. The impact of systemic therapy and possibly some immunologic benefit to the presence of low-volume metastasis is unknown. In our study, the use of adjuvant systemic therapy was prevalent, which may cloud the impact of micrometastases. It is possible that treating patients with SN micrometastases and perhaps even earlier systemic disease with adjuvant systemic therapy greatly increases their survival, obliterating any impact of SN micrometastases on survival. Our study cannot address the prognostic significance of untreated micrometastases or ITC.
It is impossible to draw any conclusion regarding the impact of adjuvant systemic therapy in this study for several reasons. The study did not randomly assign patients to receive adjuvant systemic therapy based on the size of SN metastases, and the results of SNB were not blinded and seem to have influenced treatment. However, the Early Breast Cancer Trialists' Collaborative Group 28 showed that the relative benefit from adjuvant systemic therapy was independent of axillary nodal status. In their study, the proportional risk reduction on recurrence and mortality was not influenced by nodal status.
Because the majority of patients in our study received adjuvant systemic therapy, the effect of untreated SN metastases on survival cannot truly be determined. In the American College of Surgeons Oncology Group (ACOSOG) Z0010 study, the treating physician was blinded to the presence of IHC metastasis, so treatment decisions were not based on the presence of IHC metastases, and therefore, the ACOSOG Z0010 study may better determine the significance of untreated micrometastases. The size of SN metastases may be useful in determining adjuvant systemic therapy.
Recently, some investigators have begun to question the impact of breast cancer stem cells.
29, 30 Perhaps it is not the presence of SN metastases or the size of the metastases that is important, but rather the type of cells in the SN. The presence and volume of stem cells may be predictors of metastatic disease.
Breast cancer can be a slowly evolving disease, and longer follow-up may be needed for accurate determination of the significance of micrometastases. However, as a result of the median follow-up time of 72.5 months and the fact that the majority of local and distant recurrences generally occur in the first 24 and 60 months, respectively, the length of follow-up in our study should be sufficient to see some differences. If micrometastases do have a clinically significant effect, it should be seen with this follow-up time, and it should not be completely hidden by adjuvant therapy. Conversely, it is possible that adjuvant therapy is more effective when nodal deposits are micrometastases rather than macrometastases. The ACOSOG Z0010 study and the National Surgical Adjuvant Breast and Bowel Project B-32 study may further elucidate the issues raised in the present investigation.
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